Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy
Annals of Oncology, Volume 17, No. 4, Year 2006
Notification
URL copied to clipboard!
Description
Background: Anthracycline-induced cardiotoxicity has led to the adoption of empirical dose limits that may restrict continued use of anthracyclines among patients who might benefit. Dexrazoxane, a cardioprotective agent, has been shown to reduce the risk of anthracycline-associated cardiotoxicity when given from first dose of anthracycline. This study sought to confirm the benefit of dexrazoxane in patients at high risk of cardiotoxicity due to prior anthracycline use. Patients and methods: A total of 164 female breast cancer patients, previously treated with anthracyclines, received anthracycline-based chemotherapy either with (n = 85) or without (n = 79) dexrazoxane for a maximum of six cycles. Results: Compared with those receiving anthracycline alone, patients treated with dexrazoxane experienced significantly fewer cardiac events (39% versus 13%, P < 0.001) and a lower and less severe incidence of congestive heart failure (11% versus 1%, P < 0.05). Tumor response rate was unaffected by dexrazoxane therapy. The frequency of adverse events was similar between groups and there were no significant between-group differences in the number of dose modifications/ interruptions. Conclusion: Dexrazoxane significantly reduced the occurrence and severity of anthracycline-induced cardiotoxicity in patients at increased risk of cardiac dysfunction due to previous anthracycline treatment without compromising the antitumor efficacy of the chemotherapeutic regimen. © 2006 Oxford University Press.
Authors & Co-Authors
Marty, Michael E.
France, Paris
Hôpital Saint-louis
Espié, Marc
France, Paris
Hôpital Saint-louis
Llombart-Cussac, Antonio C.
Spain, Valencia
Instituto Valenciano de Oncologia
Monnier, Alain M.
France, Montbeliard
Centre Hospitalier André Boulloche
Rapoport, Bernardo L.
South Africa, Johannesburg
Medical Oncology Centre of Rosebank
Stáhalová, Vladimira
Czech Republic, Prague
Fakultní Nemocnice Bulovka
Statistics
Citations: 187
Authors: 6
Affiliations: 5
Identifiers
Doi:
10.1093/annonc/mdj134
ISSN:
09237534
e-ISSN:
15698041
Research Areas
Cancer
Noncommunicable Diseases
Study Design
Cohort Study
Participants Gender
Female